@article{10902/32006,
year = {2023},
url = {https://hdl.handle.net/10902/32006},
abstract = {In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations},
organization = {Associazione Italiana per la Ricerca sul Cancro, Grant/Award Number: IG-25024; Consellería de Innovacion, Universidades, Ciencia y Sociedad digital, Grant/Award Number: ACIF/2021/169; Fondazione Veronesi, Grant/Award Number: 1852164; General Secretariat of Research and Innovation of Greece; Ricerca per Credere nella vita” RCV odv, Grant/Award Number: 2022-DIMED.},
publisher = {Wiley},
publisher = {American Journal of Hematology, 2023, 98(12), 1856-1868},
title = {The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: a study by ERIC, the European research initiative on CLL},
author = {Visentin, Andrea and Chatzikonstantinou, Thomas and Scarfò, Lydia and Kapetanakis, Anargyros and Demosthenous, Christos and Karakatsoulis, Georgios and Minga, Eva and Chamou, Dimitra and Allsup, David and Alonso Cabrero, Alejandro and Andres, Martín and Antic, Darko and Baile, Mónica and Baliakas, Panagiotis and Besikli-Dimou, Sortiria and Bron, Dominique and Chatzileontiadou, Sofia and Cordoba, Raúl and Yáñez San Segundo, Lucrecia and Correa, Juan Gonzálo},
}